Oregon as California moves to legalize psychedelic therapy: key lessons, costs, provider training, and regulatory guardrails

California considers legalizing supervised psychedelic therapy through SB 1012, and KQED compares its approach to Oregon’s Psilocybin Services Act, which began regulating psilocybin services in 2023. The reporting highlights that Oregon’s early results include both therapeutic success stories and serious implementation problems. The article notes Oregon’s model is drawing criticism for effectively enabling “psychedelic tourism” from out of state because service center costs can be high, such as an estimated $1,500 to $3,500 for a single psilocybin dose. It also describes hurdles in training facilitators and concerns about how guides are being used in practice. KQED connects the regulatory debate to clinical and safety context, referencing evidence that MDMA-assisted therapy can help with PTSD and depression, and the importance of set and setting to reduce negative experiences. It also explains California’s proposal would require facilitators to hold at least one medical license and create oversight and conflict-of-interest guardrails, learning from Oregon’s setbacks like bankrupt training providers and questions about “therapy” branding before FDA approval.